Livzon Pharma Wins Approval for China’s First 3‑Month Leuprorelin Microsphere – Long‑Acting GnRH Agonist Cuts Injection Frequency by 70% Across Breast Cancer, Prostate Cancer, and Precocious Puberty

Livzon Pharmaceutical Group Inc. (SHE: 000513; HKG: 1513) announced that the National Medical Products Administration (NMPA) has granted marketing approval for its Leuprorelin Acetate Microspheres for Injection, 11.25 mg (3‑month formulation), covering three core indications – premenopausal breast cancer, prostate cancer, and central precocious puberty (CPP) – making it the first 3‑month long‑acting GnRH agonist microsphere approved in China and reducing annual injection frequency from 12 to 4 (approximately 70% reduction) for patients requiring years‑long endocrine therapy.

Regulatory Milestone

Drug Profile & Mechanism of Action

• Molecule: Leuprorelin acetate – a synthetic GnRH (LHRH) agonist analogue that, when administered continuously, downregulates pituitary GnRH receptors, suppressing gonadotropin (LH/FSH) secretion and thereby reducing sex hormone (estrogen/testosterone) production to castrate or prepubertal levels
• Formulation Technology: Biodegradable microsphere sustained‑release system using Livzon’s proprietary poly‑DL‑lactide (PLA) excipient – the core rate‑controlling polymer that governs drug release kinetics over the 3‑month dosing interval
• Pharmacokinetic Advantage: The self‑developed PLA excipient enables stable, sustained drug release over 3 months with minimal blood‑level fluctuation upon repeat dosing, improving tolerability and reducing the peak‑trough variability associated with shorter‑acting formulations
• Manufacturing Innovation: Livzon is the only microsphere manufacturer in China to have achieved independent development of the core PLA excipient, enabling end‑to‑end quality control across raw materials, excipients, and finished product – a vertically integrated manufacturing capability that is exceptionally rare in the complex long‑acting injectable space
• Full Product Line: With this approval, Livzon’s leuprorelin microsphere portfolio now spans three specifications:
  • 3.75 mg (1‑month formulation, adult oncology)
  • 1.88 mg (1‑month formulation, pediatric CPP / low‑dose)
  • 11.25 mg (3‑month formulation, all three indications)

Clinical Context – Indication‑by‑Indication Analysis

1. Premenopausal Breast Cancer – Ovarian Function Suppression (OFS)

2. Prostate Cancer – Androgen Deprivation Therapy (ADT)

3. Central Precocious Puberty (CPP) – Pediatric Endocrinology

Market Impact & Outlook

• First‑in‑China Long‑Acting GnRH Microsphere: The 11.25 mg 3‑month formulation is the first long‑acting GnRH agonist microsphere of its kind approved in China, filling a significant therapeutic gap in the domestic market for extended‑release endocrine therapies. No equivalent 3‑month GnRH microsphere was previously available to Chinese patients across any of the three indications.
• Adherence‑Driven Value Proposition: The reduction from 12 to 4 annual injections (≈70% reduction) directly addresses the most significant barrier to long‑term endocrine therapy adherence – injection burden. Across breast cancer (2–5 years of OFS), prostate cancer (lifelong ADT), and CPP (≥2 years), the cumulative injection reduction translates to dozens of avoided injections per patient, with meaningful implications for treatment persistence, quality of life, and clinical outcomes.
• Self‑Developed Excipient Competitive Moat: Livzon’s status as the only Chinese microsphere company with independently developed PLA excipient technology creates a substantial manufacturing and regulatory barrier to entry for potential competitors. The vertical integration from raw material to finished product ensures supply chain security and cost advantages that are difficult to replicate.
• Global Regulatory Benchmark: Being the first GnRH product globally to complete bioequivalence studies per U.S. FDA individual drug guidance establishes a regulatory precedent that could facilitate future international registration pathways and positions Livzon as a global reference standard for GnRH microsphere quality.
• Comprehensive GnRH Product Matrix: Livzon has now assembled what the company describes as China’s most complete GnRH drug portfolio, spanning:
  • Agonists + Antagonists
  • Injectable + Oral formulations
  • 1‑month + 3‑month dosing intervals
• Oncology, Endocrinology, and Reproductive Medicine Coverage: This multi‑dimensional product matrix enables Livzon to address treatment needs across oncology (breast, prostate), pediatric endocrinology (CPP), and reproductive medicine (IVF, endometriosis), creating cross‑specialty commercial synergies.
• NRDL Reimbursement Status: Inclusion in the National Reimbursement Drug List (Category B) ensures patient affordability and hospital formulary access, supporting rapid market penetration upon commercial launch.
• Revenue Trajectory: Specific sales projections, pricing, and market‑share targets Not disclosed. The addressable patient population across the three indications encompasses hundreds of thousands of Chinese patients requiring long‑term GnRH therapy.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization, market adoption, and clinical impact of Leuprorelin Acetate Microspheres 11.25 mg in China. Marketing approval does not guarantee commercial success. Actual outcomes may differ due to risks including market competition, hospital formulary adoption timelines, prescriber switching behavior, reimbursement dynamics, competitive product launches, and the inherent uncertainties of pharmaceutical commercialization.-Fineline Info & Tech